Skip to content

Role of omega- 3 fatty acids in the treatment of periodontal diseases

Evaluation of salivary lipoxin A4 in different periodontal conditions and efficacy of omega 3 fatty acid supplement as an adjunct to nonsurgical periodontal therapy in patients having periodontitis.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/047945
Enrollment
60
Registered
2022-12-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Dietary supplementation of omega 3 PUFA: Omega -3 Fatty acid once daily for 12 weeks(Omegapure-1000mg of Omega -3 FA containing 315mg EPA & 210mg DHA) Route of administration -Oral Cont

Sponsors

DR DEVISREE RV
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Periodontally healthy individuals, patients with generalized gingivitis as well as generalized periodontitis diagnosed according to criteria given by American Academy of Periodontology 2017 classification15. ii. Patients belonging to both sexes who are willing to participate in the study.

Exclusion criteria

Exclusion criteria: I. Pregnant and lactating females II. Periodontal or orthodontic treatment at least 6 months before the start of the study III. SRP as part of initial periodontal therapy within the past 6 months IV. smokers, history of diabetes, radiation therapy, chemotherapy or patients on corticosteroid therapy. V. any diseases or disorders that compromise wound healing, VI. any history of chronic inflammatory disease and any oral mucosal inflammatory condition (e.g., aphthous, lichen planus); VII. Use of antibiotics, corticosteroids and antiâ??inflammatory drugs within 3 months before sampling. VIII. Patients on regular use of any nutritional supplements which can affect the study outcome

Design outcomes

Primary

MeasureTime frame
â?¢% Reduction in number of periodontal pockets with PPD â?¥ 4mm with bleeding on probing in group treated with adjunctive use of omega 3 PUFA and nonsurgical periodontal therapy alone. Timepoint: 0,3,6 months

Secondary

MeasureTime frame
salivary levels of lipoxin A4 measured using ELISA in group treated with adjunctive use of omega 3 PUFA and nonsurgical periodontal therapy aloneTimepoint: 0,6 months

Countries

India

Contacts

Public ContactDR DEVISREE RV

PMS College of Dental Science and Research

drdevisreenaveen@gmail.com9447361490

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026